Our results indicate that anticancer strategies employing TRAIL combined with platinum-based drugs could contribute to more effective elimination of prostate cancer cells compared to the individual action of the drugs, which warrants further investigation. This evidence concerns the gene TNFSF10 and prostate carcinoma.